A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advancedat a late stage, far along or metastatic solid tumors, including non-small-cell lung cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs (NSCLC), head and neck squamous cell carcinomacancer arising from tissues that line organs (HNSCC), melanomaa type of cancer that develops from melanocytes, which are the cells that produce pigment generally in the skin (but can develop in other areas of the body), triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectalrelating to the colon or rectum in the large bowel/intestine cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dosethe amount of medication taken escalation and dose expansion.